Last 47 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.74 | — | 4.05 | — | — | — | — | — | — | 4.23 | — | — | 31.74 | — | — | 125.52 | — | — | — | — | 8.36 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 42.65 | 126.36 | 2.57 | 6120.07 | 54.39 | 18.48 | 58.91 | 87.77 | 231.93 | 2.15 | 6652.48 | 1542.96 | 8.24 | 225.62 | 293.31 | 16.29 | 469.47 | 242.14 | 370.33 | 491.24 | 6.55 |
| — | +583.8% | -95.6% | +6872.9% | -76.6% | +759.0% | -99.1% | -94.3% | +2713.2% | -99.0% | +2168.1% | +9374.0% | -98.2% | -6.8% | -20.8% | -96.7% | +7065.6% | +2286.9% | -76.6% | +47.5% | -99.0% | |
| P/B Ratio | 1.51 | 1.78 | 1.68 | 1.83 | 1.78 | 1.01 | 1.52 | 1.53 | 1.68 | 1.95 | 2.65 | 3.47 | 4.53 | 6.24 | 4.19 | 5.23 | 7.04 | 3.12 | 3.89 | 4.94 | 7.44 |
| — | +76.6% | +10.5% | +19.7% | +5.8% | -48.4% | -42.5% | -55.9% | -62.9% | -68.7% | -36.8% | -33.6% | -35.6% | +99.9% | +7.7% | +5.8% | -5.3% | -63.1% | -9.7% | +89.6% | +290.7% | |
| P/FCF | — | — | 4.55 | — | — | — | — | — | — | 17.96 | — | — | 77.10 | — | — | — | — | — | — | — | 8.15 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 1.91 | — | — | — | — | — | — | 2.49 | — | — | 50.74 | — | — | 5137.71 | — | — | — | — | 6.99 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 1.56 | — | — | — | — | — | — | 2.25 | — | — | 51.87 | — | — | — | — | — | — | — | 7.01 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8% | 100.0% | 98.2% | -4385.7% | -1098.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -19485.8% | 31.8% | -1293.7% | -1963.4% | 26.1% | -2527.6% | -2306.2% | -2264.4% | -1782.1% | 87.1% |
| — | 0.0% | -1.8% | -4485.7% | -1198.3% | 0.0% | 0.0% | +100.5% | +214.9% | +107.7% | +105.1% | -74631.6% | +101.3% | +43.9% | +13.3% | +101.5% | -3002.8% | -3653.9% | +82.7% | +68.6% | +100.6% | |
| Operating Margin | -1905.8% | -2089.2% | 50.5% | -129576.2% | -1666.3% | -1914.4% | -2319.0% | -3056.9% | -6857.0% | 44.2% | -163056.0% | -24846.5% | 12.1% | -1654.7% | -2596.8% | -0.1% | -3317.9% | -3293.4% | -3290.9% | -2823.5% | 78.5% |
| — | -9.1% | +102.2% | -4138.9% | +75.7% | -4429.2% | +98.6% | +87.7% | -56554.0% | +102.7% | -6179.1% | -17230495.7% | +100.4% | +49.8% | +21.1% | +100.0% | -4327.5% | -7178.5% | +83.6% | +66.5% | +100.4% | |
| Net Margin | -2520.6% | -1839.9% | 64.1% | -102804.8% | -1513.1% | -2845.4% | -2128.5% | -2729.9% | -6082.6% | 50.7% | -144478.0% | -21353.2% | 25.8% | -1358.4% | -2160.6% | 12.7% | -3016.7% | -3143.6% | -3147.4% | -2831.0% | 78.5% |
| — | +35.3% | +103.0% | -3665.9% | +75.1% | -5716.0% | +98.5% | +87.2% | -23663.5% | +103.7% | -6586.9% | -168002.5% | +100.9% | +56.8% | +31.4% | +100.4% | -3943.1% | -6931.6% | +86.3% | +66.8% | +100.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.6% | -6.2% | 11.0% | -7.5% | -11.8% | -33.0% | -13.0% | -11.3% | -10.6% | 12.3% | -13.6% | -11.5% | 3.7% | -9.2% | -7.6% | 1.2% | -11.3% | -9.7% | -8.0% | -6.9% | 28.1% |
| — | +81.2% | +184.7% | +33.9% | -11.6% | -367.6% | +4.1% | +0.9% | -389.3% | +234.4% | -78.2% | -1025.8% | +132.4% | +5.8% | +4.9% | +117.8% | -140.2% | -192.2% | +54.3% | +55.6% | +303.7% | |
| ROA | -55.9% | -5.7% | 9.7% | -6.4% | -9.7% | -28.1% | -11.5% | -10.1% | -9.5% | 10.5% | -10.9% | -9.4% | 3.0% | -7.5% | -6.3% | 1.0% | -8.3% | -7.3% | -6.1% | -5.3% | 20.4% |
| — | +79.7% | +183.7% | +37.4% | -2.2% | -366.7% | -5.5% | -8.5% | -418.5% | +241.2% | -75.2% | -1066.4% | +136.0% | -2.4% | -2.5% | +118.1% | -140.6% | -207.7% | +40.9% | +40.1% | +345.5% | |
| ROIC | -2099.8% | -278.2% | — | — | — | — | -174.6% | -183.8% | -176.6% | 146.4% | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.02 | 0.02 | 0.05 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| — | -19.2% | +5.0% | +121.9% | +43.1% | +44.8% | -6.3% | +5.6% | +23.7% | +251.3% | +209.3% | +102.6% | -12.4% | -74.8% | -67.6% | -60.7% | -29.2% | -55.3% | -64.7% | -72.7% | -69.3% | |
| Debt / EBITDA | — | — | 0.29 | — | — | — | — | — | — | 0.21 | — | — | 1.02 | — | — | 52.20 | — | — | — | — | 0.13 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.72 | 25.05 | 10.43 | 7.72 | 6.61 | 5.68 | 9.00 | 10.01 | 11.52 | 12.54 | 13.08 | 11.24 | 12.94 | 9.46 | 14.33 | 14.34 | 10.37 | 13.00 | 15.22 | 17.48 | 20.81 |
| — | +340.6% | +15.9% | -22.9% | -42.6% | -54.7% | -31.2% | -10.9% | -10.9% | +32.5% | -8.7% | -21.6% | +24.8% | -27.2% | -5.9% | -18.0% | -50.2% | +67.9% | +1.4% | +51.0% | +41.0% | |
| Quick Ratio | 7.72 | 25.05 | 10.43 | 7.72 | 6.61 | 5.68 | 9.00 | 10.01 | 11.52 | 12.54 | 13.08 | 11.24 | 12.94 | 9.46 | 14.33 | 14.34 | 10.37 | 13.00 | 15.22 | 17.48 | 20.81 |
| — | +340.6% | +15.9% | -22.9% | -42.6% | -54.7% | -31.2% | -10.9% | -10.9% | +32.5% | -8.7% | -21.6% | +24.8% | -27.2% | -5.9% | -18.0% | -50.2% | +67.9% | +1.4% | +51.0% | +41.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRTA stock.
Prothena Corporation plc's current P/E is -1.7x. The average P/E over the last 1 quarters is 4.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Prothena Corporation plc's current operating margin is -1905.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Prothena Corporation plc's business trajectory between earnings reports.